Erectile dysfunction and its treatment – pharmacological and clinical profile of avanafil

Authors: T. Šrámková
Published in: Urol List 2014; 12(2): 65-67


Modern ED therapy, which in the first line consists of PDE5 inhibitors (PDE5-I) application, is safe and effective and is well tolerated. Avanafil, a new agents, is a highly potent PDE5 inhibitor and highly selective for PDE5. Results of phase III clinical trials suggest that avanafil is an effective and well tolerated treatment for ED of broad-spectrum aetiology and severity. The improvement in sexual function and tolerability coupled with the rapid onset of action and durability of effect make avanafil a viable tool for on demand treatment of ED.

Key words:
erectile dysfunction, treatment, phosphodiesterase 5 inhibitors, avanafil


1. Weiss P, Zvěřina J. Sexuální chování v ČR –  situace a trendy. 1. ed. Praha: Portál 2001.

2. Šrámková T. Poruchy sexuality u somaticky nemocných a jejich léčba. Praha: Grada Publishing 2013.

3. Wespes E, Eardley I, Giuliano F et al. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. Guidelines EAU 2013. Available from: http:/ / gls/ pdf/ 14_Male%20Sexual%20Dysfunction_LR.pdf.

4. Státní ústav pro kontrolu léčiv. SmPC sildenafil, tadalafil, vardenafil 2013. [online]. Dostupné z: modules/ medication.

5. Salonia A, Burnett AL, Graefen M et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. Eur Urol 2012; 62(2): 261– 272. doi: 10.1016/ j.eururo.2012.04.046.

6. Státní ústav pro kontrolu léčiv. SmPC avanafil 2013. [online]. Dostupné z: modules/ medication.

7. Goldstein I, McCullough AR, Jones LA et al. A randomized, double‑blind, placebo– controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012; 9(4): 1122– 1133. doi: 10.1111/ j.1743‑ 6109.2011.02629.x.

8. Goldstein I, Jones LA, Belkoff LH et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double‑blind study in men with diabetes mellitus. Mayo Clin Proc 2012; 87(9): 843– 852. doi: 10.1016/ j.mayocp.2012.06.016.

9. Mulhall JP, Moul JW, Wang R et al. A phase III, placebo- controlled study of the safety and efficacy of avanafil in the treatment of erectile dysfunction fol­lowing bilateral nerve– sparing radical prostatectomy. J Sex Med 2012; 9: S42– S43.

10. Belkoff LH, McCullough A, Goldstein I et al. An open- label, long‑term evaluation of the safety, efficacy and tolerability of avanafil in male patiens with mild to severe erectile dysfunction. Int J Clin Pract 2013; 67(4): 333– 341. doi: 10.1111/ ijcp.12065.

11. Alwaal A, Al- Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: focus on avanafil. Drug Des Devel Ther 2011; 5: 435– 443. doi: 10.2147/ DDDT.S15852.

12. Vyhnánková V, Pacík D, Čermák A. Vývoj medikamentózní terapie ED –  minulost, současnost, budoucnost. Urol List 2014; 12(1): 19– 23.

Paediatric urologist Urology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account